Using the PBPK/PD model of SGLT2 inhibitors, our study analyzed the reabsorption capacity of the SGLT transporter system in patients with CKD and found that in patients with T2DM and moderate or severe renal insufficiency, the reabsorption capacity of the SGLT1 transporter decreased by 15% and 50%, respectively, while that of the SGLT2 transporter decreased by 60% and 90%, respectively (see Supplementary Table S3). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.